About the event
AstraZeneca’s ‘Reframing COPD’ Regional Forum aims to provide local leaders in respiratory medicine with an opportunity to share best-practices and discuss patient pathways specific to regional settings. Through interactive discussions and workshops; some of the most important topics relevant to COPD management within secondary care will be explored; including addressing cardiopulmonary risk and premature death; implementing guidance into practice; and the importance of timely treatment optimisation for patients with COPD. This meeting will be an opportunity to reflect on incremental changes that can collectively drive practice change to enable meaningful advancements in COPD management; reframing how care is delivered.
Send an enquiry
AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines. Our Purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve our Purpose is to put science at the centre of everything we do. Science defines who we are. It is why we come to work every day and is part of our DNA. But this is only half of the story. We know that we do not have all the answers. We want to share ideas because we believe it results in better medicines. We want the way we work to be inclusive, open and collaborative. This approach runs through all that we do.
Want to learn more?
Similar CPD Events
Healthcare & Medical
This Week
Calquence National Summit
AstraZeneca
The Calquence National Summit is a promotional and educational event hosted and funded by AstraZenec...
London,
19 Oct 2024
Healthcare & Medical
This Week
HER2 Horizons National Meeting
AstraZeneca
The HER2 Horizons National Meeting is a promotional and educational event hosted and funded by Astra...
Holborn,
18 Oct 2024
Healthcare & Medical
This Week
Calquence National Summit
AstraZeneca
The Calquence National Summit is a promotional and educational event hosted and funded by AstraZenec...
London,
18 Oct 2024